CELLULAR BRAILLE

DRUG DISCOVERY SERVICES, NAMELY SCREENING NUCLEAR RECEPTORS BY USING SURROGATE LIGANDS TO PROFILE SELECTIVE RECEPTOR MODULATORS IN VIVO AND CLASSIFYING DRUG LEADS INTO GROUPS OF TISSUE SELECTIVE AGONISTS AND ANTAGONISTS